IBI3001 in Participants With Unresectable, Locally Advanced or Metastatic Solid Tumors

September 22, 2026 updated by: Fortvita Biologics (USA)Inc.

A Phase 1 Study of IBI3001 in Participants With Unresectable, Locally Advanced or Metastatic Solid Tumors

This is a Phase 1 multicenter, multi-regional, open-label, first-in-human study of IBI3001 in participants with unresectable, locally advanced or metastatic solid tumors. The purpose of this study is to identify the MTD/RP2D of IBI3001, and to explore the preliminary efficacy of IBI3001.

Study Overview

Status

Recruiting

Conditions

Intervention / Treatment

Study Type

Interventional

Enrollment (Estimated)

250

Phase

  • Phase 1

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Contact

Study Locations

    • New South Wales
      • Wollongong, New South Wales, Australia, 2500
    • South Australia
      • Adelaide, South Australia, Australia, 5000
    • Anhui
      • Hefei, Anhui, China, 230022
        • Recruiting
        • The First Affiliated Hospital of Anhui Medical University
        • Contact:
    • Beijing Municipality
      • Beijing, Beijing Municipality, China, 100021
        • Recruiting
        • Cancer Hospital, Chinese Academy of Medical Sciences
        • Contact:
      • Beijing, Beijing Municipality, China, 100853
        • Recruiting
        • Chinese People's Liberation Army General Hospital
        • Contact:
    • Fujian
      • Fuzhou, Fujian, China, 350014
      • Fuzhou, Fujian, China, 350005
        • Recruiting
        • First Affiliated Hospital, Fujian Medical University
        • Contact:
    • Guangxi
      • Nanning, Guangxi, China, 530021
        • Recruiting
        • The Affiliated Tumor Hospital of Guangxi Medical University
        • Contact:
    • Heilongjiang
      • Harbin, Heilongjiang, China, 150081
    • Henan
      • Anyang, Henan, China, 455100
      • Luoyang, Henan, China, 471003
        • Recruiting
        • The First Affiliated Hospital of Henan University of Science and Technology
        • Contact:
      • Zhengzhou, Henan, China, 450008
      • Zhengzhou, Henan, China, 450052
        • Recruiting
        • The First Affiliated Hospital of Zhengzhou University
        • Contact:
    • Hubei
      • Wuhan, Hubei, China, 430022
        • Recruiting
        • Wuhan Union Hospital, Tongji Medical College, Huazhong University of Science and Technology
        • Contact:
    • Hunan
      • Changsha, Hunan, China, 410008
    • Jiangsu
      • Nanjing, Jiangsu, China, 210008
        • Recruiting
        • Nanjing Drum Tower Hospital, Affiliated Hospital of Medical School, Nanjing University
        • Contact:
      • Nanjing, Jiangsu, China, 210029
        • Recruiting
        • Jiangsu Province Hospital (The First Affiliated Hospital of Nanjing Medical University)
        • Contact:
    • Jiangxi
      • Nanchang, Jiangxi, China, 330029
    • Shanghai Municipality
      • Shanghai, Shanghai Municipality, China, 200120
        • Recruiting
        • Shanghai East Hospital, Tongji University School of Medicine
        • Contact:
    • Sichuan
      • Chengdu, Sichuan, China, 610041
      • Chengdu, Sichuan, China, 610041
    • Zhejiang
      • Hangzhou, Zhejiang, China, 310022
      • Hangzhou, Zhejiang, China, 310003
        • Recruiting
        • The First Affiliated Hospital, Zhejiang University School of Medicine
        • Contact:
    • California
      • Los Angeles, California, United States, 90025
    • New Jersey
      • East Brunswick, New Jersey, United States, 08816
    • Texas
      • Dallas, Texas, United States, 75039
    • Virginia
      • Fairfax, Virginia, United States, 22031
        • Active, not recruiting
        • Virginia Cancer Specialists

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

18 years and older (Adult, Older Adult)

Accepts Healthy Volunteers

No

Genders Eligible for Study

All

Description

Key Inclusion Criteria:

  1. Male or female participants ≥ 18 years old;
  2. Has an Eastern Cooperative Oncology Group (ECOG) performance status (PS) of 0 or 1;
  3. Has an anticipated life expectancy of ≥ 12 weeks;
  4. Adequate bone marrow and organ function:
  5. At least 1 evaluable lesion according to Response Evaluation Criteria in Solid Tumors (RECIST) Version 1.1. for dose escalation , and 1 measurable lesion for dose expansion.
  6. Has a documented (histologically- or cytologically-proven), unresectable, locally advanced or metastatic solid tumor that is refractory to or intolerable with standard treatment, or for which no standard treatment is available; participants who refuse standard therapy, or are able to suspend standard therapy without major risks.

Key Exclusion Criteria:

  1. Progressed or refractory to an ADC that consists of an Exatecan derivative that is a topoisomerase I inhibitor or intolerable with an ADC that consists of Exatecan;
  2. Plan to receive other antitumor therapy during the study excluding palliative radiotherapy for the purpose of symptom (like pain) relief that must also not have an impact on tumor assessment throughout the study;
  3. Pyloric obstruction and/or persistent recurrent vomiting (≥ 3 times in 24 hours);
  4. Gastrointestinal perforation and/or fistula within 6 months prior to first administration of the study drug, and not recovered after surgical treatment;
  5. Known symptomatic central nervous system (CNS) metastases.
  6. History of pneumonia requiring corticosteroids therapy, or history of clinically significant lung diseases; Uncontrolled diseases;
  7. History of endotracheal or gastrointestinal stent implantation;
  8. Ascites, pleural effusion, or pericardial effusion with symptoms and requiring intervention;
  9. Esophageal or gastric varices requiring immediate intervention;
  10. Not eligible to participate in this study at the discretion of the investigator;
  11. Do not have adequate treatment washout period before study drug administration. -

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Primary Purpose: Treatment
  • Allocation: N/A
  • Interventional Model: Single Group Assignment
  • Masking: None (Open Label)

Arms and Interventions

Participant Group / Arm
Intervention / Treatment
Experimental: Open-label: IBI3001 monotherapy

The provisional dose levels are planned to be evaluated, but it is possible for additional and/or intermediate dose levels to be added during the study.

IBI3001 is proposed to be administered by intravenous infusion (IV)

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Number of subjects with adverse events
Time Frame: 24 months

Occurrence and severity of adverse events (AEs), with severity determined by NCI CTCAE v5.0 criteria

24 months
Number of subjects with clinically significant changes in physical examination results
Time Frame: 24 months

Clinically significant abnormal physical examination findings reported by the investigator.

24 months
Number of subjects with clinically significant changes in vital signs
Time Frame: 24 months

Vital signs including body temperature, pulse, respiratory rate, SpO2 and blood pressure

24 months
MTD or RP2D of IBI3001 Number of subjects with dose-limiting toxicities (DLTs)
Time Frame: 24 months

Dose limiting toxicity (DLT) to establish MTD or RP2D

24 months

Secondary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Plasma concentration (Cmax) of IBI3001
Time Frame: 24 months

Plasma concentration of IBI3001 for single and multiple doses.

24 months
Area under the curve (AUC) of IBI3001
Time Frame: 24 months

AUC of IBI3001 for single and multiple doses

24 months
Time to maximum concentration (Tmax) of IBI3001
Time Frame: 24 months

Tmax of IBI3001 for single and multiple doses.

24 months
Clearance (CL) of IBI3001
Time Frame: 24 months

Clearance of IBI3001 from the plasma

24 months
Volume of distribution (V) of IBI3001
Time Frame: 24 months

Apparent volume of distribution of IBI3001

24 months
Half-life (T1/2) of IBI3001
Time Frame: 24 months

T1/2 of IBI3001 for single and multiple doses

24 months
Immunogenicity of IBI3001
Time Frame: 24 months

Incidence of anti-drug (IBI3001) antibody

24 months
Objective response rate (ORR)
Time Frame: 24 months

ORR as evaluated per the RECIST v1.1 criteria

24 months
Duration of response (DoR)
Time Frame: 24 months

DoR as evaluated per the RECIST v1.1 criteria

24 months
Disease control rate (DCR)
Time Frame: 24 months

DCR as evaluated per the RECIST v1.1 criteria

24 months
Time to response (TTR)
Time Frame: 24 months

TTR as evaluated per the RECIST v1.1 criteria

24 months
Progression free survival (PFS)
Time Frame: 24 months

PFS as evaluated per the RECIST v1.1 criteria

24 months
Overall survival (OS)
Time Frame: 24 months

Overall survival.

24 months

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Sponsor

Collaborators

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Actual)

January 10, 2025

Primary Completion (Estimated)

December 31, 2026

Study Completion (Estimated)

December 31, 2027

Study Registration Dates

First Submitted

April 1, 2024

First Submitted That Met QC Criteria

April 1, 2024

First Posted (Actual)

April 5, 2024

Study Record Updates

Last Update Posted (Actual)

September 25, 2026

Last Update Submitted That Met QC Criteria

September 22, 2026

Last Verified

September 1, 2026

More Information

Terms related to this study

Other Study ID Numbers

  • CIBI3001A101

Plan for Individual participant data (IPD)

Plan to Share Individual Participant Data (IPD)?

NO

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

Yes

Studies a U.S. FDA-regulated device product

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.